🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Capsule(s) Serving Size
90 Servings
Non-Nutrient/Non-Botanical Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

Pamitoylethanolamide
350 mg
50 mg
📊 Market median: 167.0mg (311 products) 📚 182 studies (Tier A: 0, B: 65)
This product: 50mg

Other Ingredients

Hypromellose Ascorbyl Palmitate Silicon Dioxide Microcrystalline Cellulose

Label Claims — Verification

All Other
Structure/Function
All Other (99% of products) Structure/Function (92% of products) Nutrient (8% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free

Product Information

📋 Directions for Use

Suggested use: Take 1 capsule twice daily or as directed by your healthcare practitioner.

⚠️ Warnings & Precautions

Caution: Keep out of reach of children. Consult with your healthcare practitioner on proper dosage for children under 5 years of age.

If you are pregnant or nursing please consult with your healthcare practitioner.

Professional use only

🧪 Formulation Notes

Palmitoylethanolamide (PEA) is a bio-identical fatty acid amide that is normally synthesized by healthy tissue in the human body in response to inflammation. PEA is made by various plants and animals and is present throughout the animal kingdom. PEA can be found in many different tissues including glia, neurons, retina, white blood cells, mast cells and adipocytes.

Supplementing with PEA has been scientifically shown to naturally assist in the reduction of inflammation and to have neuro-protective and possibly pain control effects.

Exclusive formula Enhanced formula Professional grade

Non GMO Palmitoylethanolamide

Gluten free

Additional Information

GMP Good Manufacturing Practice Consistent Quality

Product Details

UPC / SKU 8 54998 00650 2
DSLD Entry Date 2025-05-21
Product Type Non-Nutrient/Non-Botanical
Form Capsule
DSLD ID 327698
Data Updated 2026-04-11

Research Evidence

193 Research Sources
55 Avg Quality Score
92 Systematic Review
83 Meta Analysis
9 Rct
7 Clinical Trial
1 Openfda Safety
B Effects of resveratrol supplementation on risk factors of non-communicable diseases: A meta-analysis of randomized controlled trials
Meta Analysis Critical reviews in food science and nutrition 2018
B Resveratrol for adults with type 2 diabetes mellitus
Meta Analysis The Cochrane database of systematic reviews 2020
B Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities
Systematic Review International journal of molecular sciences 2024
B Endocrine disrupting chemicals and breast cancer: a systematic review of epidemiological studies
Systematic Review Critical reviews in food science and nutrition 2022
B Can resveratrol supplement change inflammatory mediators? A systematic review and meta-analysis on randomized clinical trials
Meta Analysis European journal of clinical nutrition 2019
B Effects of resveratrol supplementation on bone biomarkers: a systematic review and meta-analysis
Meta Analysis Annals of the New York Academy of Sciences 2019
B The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials
Meta Analysis Critical reviews in food science and nutrition 2020
B Resveratrol supplementation and type 2 diabetes: a systematic review and meta-analysis
Meta Analysis Critical reviews in food science and nutrition 2022
B Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials
Meta Analysis Clinical nutrition (Edinburgh, Scotland) 2015
B Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis
Meta Analysis Nutrients 2020
View all evidence for Resveratrol →

Compare Similar Products

View all Resveratrol products →